Following Pfizer’s exit, Shionogi’s holding increases to 21.7%, with GSK maintaining 78.3% majority share.
GSK press release
20 January 2026 — GSK plc and Shionogi & Co., Ltd today announced that they have reached agreement together with Pfizer Inc. for the 11.7% economic interest in ViiV Healthcare Limited currently held by Pfizer to be replaced with an investment by Shionogi. As a result of this transaction, Shionogi will increase its economic interest in ViiV Healthcare to 21.7%. GSK will maintain its 78.3% majority owned economic interest. Shionogi will continue to have one Director position on the ViiV Healthcare Board.
ViiV Healthcare, the global specialist HIV company, is dedicated to delivering advances in treatment and care for people living with HIV and for people who could benefit from HIV prevention.
Read the full press release here.
Source : GSK
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.